Key Takeaways
- Accenture (ACN) beats Q2 revenue and EPS estimates but sees shares pressured after providing a full-year earnings outlook that fell slightly below analyst consensus.
- Eli Lilly (LLY) reports 15.3% weight loss in its Phase 3 trial of Retatrutide for type 2 diabetes, marking a significant milestone for its triple-agonist pipeline.
- Iran claims the arrest of 97 "soldiers of Israel" as regional tensions escalate following threats of further retaliation against energy infrastructure.
- 3M (MMM) enters a $1.95 billion deal with Bain Capital to acquire Madison Fire & Rescue, aiming to create a dominant global fire and safety joint venture.
- Russia signals a potential preventive fuel export ban to control domestic price surges, adding further uncertainty to global energy markets.
Corporate Earnings and M&A Activity
Accenture (ACN) reported second-quarter fiscal 2026 revenue of $18.0 billion, surpassing analyst estimates of $17.84 billion. The professional services giant posted an adjusted EPS of $2.93, beating the $2.85 consensus. Despite the beat, the company’s full-year adjusted EPS guidance of $13.65 to $13.90—with a midpoint of $13.78—trailed the investor expectation of $13.86, leading to a cautious reaction in early trading.
In a major industrial move, 3M (MMM) announced a definitive agreement to acquire Madison Fire & Rescue in partnership with Bain Capital for $1.95 billion. Under the deal, 3M will contribute its Scott Safety business to a new joint venture, retaining a 50.1% stake and receiving $700 million in cash proceeds. The transaction is expected to close in the second half of 2026, targeting enhanced margins in the high-priority safety vertical.
Healthcare Breakthroughs
Eli Lilly (LLY) announced positive topline results from its TRANSCEND-T2D-1 Phase 3 clinical trial. The study revealed that Retatrutide, a triple hormone receptor agonist, led to a 15.3% weight loss (approximately 33.3 lbs) in adults with type 2 diabetes over a 40-week period. This result significantly outperformed the placebo group and demonstrated meaningful improvements in cardiovascular risk factors, including blood pressure and cholesterol levels.
Geopolitical Tensions and Energy Risks
The Middle East conflict reached a new flashpoint as Iran’s Intelligence Ministry announced the arrest of 97 individuals described as "soldiers of Israel." Iranian Parliament Speaker Mohammad Bagher Ghalibaf mocked recent Israeli and U.S. military claims regarding the destruction of Iranian missile launchers. Ghalibaf sarcastically noted that while enemies claim to have destroyed 320% of Iran's launchers, the country continues high-rate launches, leading the "enemy" to now target a "500% destruction" rate.
Energy markets remain on edge as Iran’s armed forces warned that retaliation for attacks on its energy infrastructure is "not yet complete." This follows reports of missile strikes hitting the Ras Laffan energy hub in Qatar. Simultaneously, Russia’s Energy Ministry official Anton Rubtsov stated that Moscow may introduce a preventive fuel export ban if domestic prices continue to rise, a move intended to curb internal inflation but likely to tighten global supply.
Global Trade and Economic Indicators
The European Parliament is set to hold a critical vote next week on a major trade deal with the United States. The "Turnberry" deal, which aims to scrap tariffs on hundreds of industrial and agricultural goods, advanced through the trade committee today. Lawmakers added a "sunrise clause" making EU tariff reductions conditional on U.S. compliance, reflecting lingering distrust in the transatlantic relationship.
In North America, small business sentiment in Canada saw a sharp decline. The CFIB Business Barometer for March dropped to 55.8, down from a previous reading of 64.8. Meanwhile, diplomatic schedules shifted as a working lunch between Donald Trump and Japanese Prime Minister Sanae Takaichi was cancelled to allow more time for an extended formal summit meeting.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.